The World Health Organisation’s Technical Advisory Group has recommended that the Ervebo vaccine be prioritised for a randomised clinical trial against Bundibugyo virus disease in the Democratic Republic of Congo.
The recommendation followed preliminary animal-study findings suggesting that Ervebo may provide some cross-protection against the virus, particularly in reducing deaths. WHO said experts found no identified safety concerns with the vaccine for use among contacts of confirmed cases.
However, the advisory group stressed that Ervebo’s effectiveness against Bundibugyo virus and its ability to prevent transmission have not yet been established and must be evaluated through clinical research.
Ervebo is currently the only licensed Ebola vaccine, but it was developed specifically against Ebola virus disease caused by the Ebola Zaire virus. WHO said a vaccine specifically targeting Bundibugyo virus remains the preferred option, although sufficient data on such candidates are not currently available.
The recommendation comes as health authorities intensify efforts to contain the Bundibugyo virus outbreak in the Democratic Republic of Congo, with WHO emphasising the need for further research, increased vaccine production and improved access if future evidence confirms the vaccine’s effectiveness.
